265 related articles for article (PubMed ID: 31349879)
1. Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer.
Cai L; Bai H; Duan J; Wang Z; Gao S; Wang D; Wang S; Jiang J; Han J; Tian Y; Zhang X; Ye H; Li M; Huang B; He J; Wang J
J Immunother Cancer; 2019 Jul; 7(1):198. PubMed ID: 31349879
[TBL] [Abstract][Full Text] [Related]
2. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
[TBL] [Abstract][Full Text] [Related]
3. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
[TBL] [Abstract][Full Text] [Related]
4. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
[TBL] [Abstract][Full Text] [Related]
5. [Multi-classification prediction model of lung cancer tumor mutation burden based on residual network].
Meng X; Yu C; Yang X; Yang Z; Liu D
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2023 Oct; 40(5):867-875. PubMed ID: 37879915
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
7. High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study.
Talvitie EM; Vilhonen H; Kurki S; Karlsson A; Orte K; Almangush A; Mohamed H; Liljeroos L; Singh Y; Leivo I; Laitinen T; Kallajoki M; Taimen P
Neoplasia; 2020 Sep; 22(9):333-342. PubMed ID: 32585428
[TBL] [Abstract][Full Text] [Related]
8. Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma.
Nagahashi M; Sato S; Yuza K; Shimada Y; Ichikawa H; Watanabe S; Takada K; Okamoto T; Okuda S; Lyle S; Takabe K; Tsuchida M; Wakai T
J Surg Res; 2018 Oct; 230():181-185. PubMed ID: 30072189
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
10. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma.
Luo R; Song J; Xiao X; Xie Z; Zhao Z; Zhang W; Miao S; Tang Y; Ran L
Aging (Albany NY); 2020 Jul; 12(14):14649-14676. PubMed ID: 32723974
[TBL] [Abstract][Full Text] [Related]
11. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
12. Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers.
Ruel LJ; Li Z; Gaudreault N; Henry C; Saavedra Armero V; Boudreau DK; Zhang T; Landi MT; Labbé C; Couture C; Desmeules P; Joubert P; Bossé Y
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2219-2227. PubMed ID: 36126278
[TBL] [Abstract][Full Text] [Related]
13. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
14. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.
Zhang N; Wu J; Yu J; Zhu H; Yang M; Li R
Clin Lung Cancer; 2020 May; 21(3):e151-e163. PubMed ID: 31734072
[TBL] [Abstract][Full Text] [Related]
15. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T; Udagawa H; Matsumoto S; Yoh K; Nosaki K; Ikeda T; Zenke Y; Kirita K; Niho S; Akimoto T; Goto K; Ishii G
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1227-1237. PubMed ID: 32997195
[TBL] [Abstract][Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
17. Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease.
Kobayashi H; Serizawa M; Naito T; Konno H; Kojima H; Mizuno T; Isaka M; Endo M; Nagashima T; Kusuhara M; Urakami K; Ohshima K; Yamaguchi K; Ohde Y; Takahashi T
Respirology; 2020 Aug; 25(8):850-854. PubMed ID: 31694070
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
[TBL] [Abstract][Full Text] [Related]
19. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.
van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM
Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer.
Chang H; Sasson A; Srinivasan S; Golhar R; Greenawalt DM; Geese WJ; Green G; Zerba K; Kirov S; Szustakowski J
Mol Diagn Ther; 2019 Aug; 23(4):507-520. PubMed ID: 31250328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]